Cologuard Maker Exact Sciences Reports Big Sales and a Surprise Profit

Cancer-testing company

Exact Sciences

hadn’t expected to report cash profits until this year’s September quarter. But the seller of the Cologuard test said that a jump in December quarter sales helped delivered profits ahead of schedule.

Revenue rose 28% in 2022’s final quarter to more than $550 million, according to preliminary numbers announced by the Madison, Wis., company on Sunday. Sales of screening products like the Cologuard stool test for colorectal cancer jumped more than 40%.